These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

867 related items for PubMed ID: 29525970

  • 21. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K.
    Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
    [Abstract] [Full Text] [Related]

  • 22. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW.
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [Abstract] [Full Text] [Related]

  • 23. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Lee DR, Lee J.
    Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
    [Abstract] [Full Text] [Related]

  • 24. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS, Chua SS, Chew YY, Chan SP.
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [Abstract] [Full Text] [Related]

  • 25. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
    Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA.
    J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
    Bae SJ, Kim BJ, Lim KH, Lee SH, Kim HK, Kim GS, Koh JM.
    J Bone Miner Metab; 2012 Sep; 30(5):588-95. PubMed ID: 22610063
    [Abstract] [Full Text] [Related]

  • 27. A dedicated Fracture Liaison Service telephone program and use of bone turnover markers for evaluating 1-year persistence with oral bisphosphonates.
    van den Berg P, van Haard PMM, van der Veer E, Geusens PP, van den Bergh JP, Schweitzer DH.
    Osteoporos Int; 2018 Apr; 29(4):813-824. PubMed ID: 29260291
    [Abstract] [Full Text] [Related]

  • 28. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
    McClung MR, Balske A, Burgio DE, Wenderoth D, Recker RR.
    Osteoporos Int; 2013 Jan; 24(1):301-10. PubMed ID: 23079690
    [Abstract] [Full Text] [Related]

  • 29. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI.
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [Abstract] [Full Text] [Related]

  • 30. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 31. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D.
    Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
    [Abstract] [Full Text] [Related]

  • 32. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 34. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [Abstract] [Full Text] [Related]

  • 35. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.
    Clin Drug Investig; 2006 Sep; 26(2):63-74. PubMed ID: 17163237
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
    Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD.
    Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
    [Abstract] [Full Text] [Related]

  • 37. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W, Sun J, Zhou L, Li Y, Wu X.
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [Abstract] [Full Text] [Related]

  • 38. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH.
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [Abstract] [Full Text] [Related]

  • 39. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M, Tuzun C, Unlu Z, Tikiz C, Taneli F, Uyanik BS.
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [Abstract] [Full Text] [Related]

  • 40. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
    Roberts J, Castro C, Moore AE, Fogelman I, Hampson G.
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.